Journal of Biosafety and Biosecurity最新文献

Since its emergence, SARS-CoV-2 virus, the causative agent of COVID-19, has undergone over three years of evolutionary changes. Throughout this evolutionary process, multiple variants, such as Alpha, Beta, Gamma, Delta, and Omicron, have emerged, leading to widespread outbreaks and pandemics. A comprehensive analysis of the evolution of SARS-CoV-2 over the past three years reveals its progression through three distinct stages.

Availability of mobile laboratories can facilitate rapid on-spot detection of pathogens, monitor its presence in certain populations and inform health authorities to take immediate remedial measures. Currently available biosafety and biosecurity guidelines and policies may not completely articulate the increased demand to manage mobile units in infectious disease outbreaks in remote parts of the country for rapid diagnosis, and also allows research and epidemiological study take place appropriately.

The main objective of this study is to evaluate the current limitations and develop and implement biosafety and biosecurity guidelines as well as the protocols for operations, security, and response plan of mobile biosafety level 2 laboratories and their deployment.

Keeping in view the sensitivity of it, a comprehensive plan was developed to address it in view of Global Health Security framework. Biosafety and biosecurity protocols were developed including Risk Assessment Tool (RAT) fitting the needs and strengthen the diagnostic and epidemiological capacity in the field covering remote parts of country to fill the gaps observed during the COVID-19 pandemic.

Currently the biosafety and biosecurity best practices guidelines and biosecurity policy and regulations are directed mostly towards static laboratories. A biosafety and biosecurity manual developed to adopt and meet the requirements for MBSL 2. For acute health infectious threats including the COVID-19 outbreak and other epidemics, rapid diagnosis can curb and mitigate the problem before it gets out of its boundaries creating significant health risks for the public and economy. The deployment of mobile laboratories will certainly help in curbing these catastrophes.

Routine microbial inactivation procedures used in microbiology laboratories must be verified. In this study, the efficacy of surface disinfection using 70% Isopropanol, 0.45% Presept, and 1% Virkon was tested against 24 bacterial strains commonly handled in aquaculture microbiology laboratories. Isopropanol was ineffective against Nocardia asteroides NCIMB 1290, while Virkon was not effective against Aeromonas eucrenophila NCIMB 74 or Pediococcus acidilacti R52037.

The Nipah virus (NiV) infection is one of the newly emerging deadly zoonotic diseases which carries a significant weightage of mortality among its victims. Due to the relatively recent history of its emergence and only a few known outbreaks, we cannot predict but foresee its potential to create havoc, which can be far more dreadful than the current ongoing COVID-19 pandemic. Here we have tried to depict the fatal potential of the virus and the increased propensity with which it can spread to rest of the world.

The emergence and prevalence of multidrug-resistant Acinetobacter baumannii (MRAB) poses a huge challenge to clinical treatment. To investigate the genetic and epidemiologic characteristics of MRAB in Liaocheng, China, and to explore potential resistance mechanisms, 56 MRAB strains were collected from the clinical departments of seven hospitals in Liaocheng between 2020 and 2022. Molecular typing, antimicrobial resistance patterns, and epidemiological characteristics were determined by genome sequencing and comparative genome analysis. Sequence type (ST) 540 was the most prevalent ST of the 56 MRAB in Liaocheng, and most strains (92.86%) were grouped into CC92. Core genome multilocus sequence typing subdivided the strains according to the number of allelic differences and could distinguish different outbreaks caused by ST540 isolates in the hospitals. All the isolates harbored bla_OXA-23 and bla_ADC-25, and at least 92.86% of the isolates were resistant to 10 antibiotics. The major MRAB epidemic clone detected in Liaocheng was ST540, which was different from the results reported in other regions in China. Furthermore, several inter-hospital transmissions of ST540 isolates were observed. The findings highlight the urgent need for effective nosocomial infection control measures and the continuous surveillance of ST540 MRAB in Liaocheng.

Ebola virus (EBOV) is classified as a category A pathogen as it causes viral hemorrhagic fever, one of the most-deadly virus-related diseases. Since its discovery in 1976, EBOV has caused a number of global public health incidents, which have posed a serious threat to both humans and non-human primates. Thus, numerous preventive vaccine studies are underway, including research on inactivated vaccines, DNA vaccines, subunit vaccines, virus-like particles, Venezuelan equine encephalitis virus replicon particles, and several viral vector vaccines. The vesicular stomatitis virus-based vaccine Ervebo was recently approved by the Food and Drug Administration and the European Union, and several other vaccines have also been proven to confer potent protection in non-human primates against EBOV lethal challenge. This review provides a brief background of EBOV, with a focus on the epidemiology, available animal models, and advances in preventive approaches for EBOV infection.

Synthetic biology is an emerging multidisciplinary field that aims to design and construct new biological systems not found in nature. Whereas synthetic biology may yield tremendous benefits, it may also pose substantial risks to human health and the environment that must be addressed. In this paper, we examined the environmental risks associated with synthetic biology, including changes to or depletion of the environment, competition with native species, horizontal gene transfer, pathogenicity or toxicity, bioterrorism, and laboratory biosecurity. We highlight three approaches for assessing environmental risks in synthetic biology: solution-focused risk assessment, Bayesian networks, and network of networks for sustainable capacity building. An ethical governance framework is proposed to facilitate innovation while minimising risks. This framework emphasises the precautionary principle and balancing stakeholder interests prior to project development and commercialisation. Overall, we underscore the importance and urgency of assessing and managing the environmental risks of synthetic biology to ensure its safe and ethical development and application.